Oppenheimer & Co’s Grace Therapeutics GRCE Stock Holding History

Oppenheimer & Co’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$21.5K	Hold	10,000	–	–	﹤0.01%	1744
2026 Q2	$22.7K	Hold	10,000	–	–	﹤0.01%	1752
2026 Q1	$46.3K	Buy	+10,000	New	+$39.3K	﹤0.01%	1664
2021 Q1	–	Sell	-4,687	Closed	-$73K	–	1508
2020 Q4	$73K	Buy	4,687 +629	+16%	+$7.27K	﹤0.01%	1320
2020 Q3	$39K	Sell	4,058 -75	-2%	-$1.95K	﹤0.01%	1267
2020 Q2	$93K	Hold	4,133	–	–	﹤0.01%	1209
2020 Q1	$75K	Buy	4,133 +2,582	+166%	+$91.4K	﹤0.01%	1137
2019 Q4	$182K	Buy	1,551 +402	+35%	+$39.7K	﹤0.01%	1196
2019 Q3	$104K	Buy	+1,149	New	+$106K	﹤0.01%	1212

Other funds holding GRCE

Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.47B AUM 20.38% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Oppenheimer & Co's GRCE Position: Q3 2026 in Review

Oppenheimer & Co held its Grace Therapeutics (GRCE) position steady in Q3 2026 at 10,000 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1744.

Oppenheimer & Co first reported a position in GRCE in Q3 2019 and has held it in 9 quarters since. The position peaked at $182K in Q4 2019. 6 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.

Oppenheimer & Co held 10,000 shares of Grace Therapeutics worth $21.5K as of Q3 2026.
Oppenheimer & Co left its Grace Therapeutics share count unchanged in Q3 2026.
Grace Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1744 holding.
Oppenheimer & Co first reported a position in Grace Therapeutics in Q3 2019 and has held it in 9 quarters since.
Oppenheimer & Co's Grace Therapeutics position peaked at $182K in Q4 2019.
6 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.